UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status No longer recruiting
Unique ID issued by UMIN UMIN000035853
Receipt No. R000040841
Official scientific title of the study Retrospective study of alectinib on long-term prognosis in poor performance status patients with ALK positive, advanced/recurrent NSCLC
Date of disclosure of the study information 2019/02/12
Last modified on 2019/02/12

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Official scientific title of the study Retrospective study of alectinib on long-term prognosis in poor performance status patients with ALK positive, advanced/recurrent NSCLC
Title of the study (Brief title) LOGIK1401-B
Region
Japan

Condition
Condition Non-Small Cell Lung Cancer
Classification by specialty
Pneumology Hematology and clinical oncology
Classification by malignancy Malignancy
Genomic information NO

Objectives
Narrative objectives1 The observation period of "PhaseII safety and efficacy study of alectinib in poor performance status patients with ALK positive, advanced NSCLC (LOGIK1401)" was finished at 1.5 years after the completion of enrollment of 18 patients. The aim of this study is to follow-up the examination on progression free survival (PFS) and overall survival (OS) as well as 1-year and 2-year overall survival, pattern of progression (e.g. presence or absence of progression of brain metastasis) and post-treatment is performed in this study, and we also clarify.
Basic objectives2 Efficacy
Basic objectives -Others
Trial characteristics_1 Exploratory
Trial characteristics_2
Developmental phase Not applicable

Assessment
Primary outcomes Progression free survival (PFS)
Overall survival (OS)
One-year overall survival
Two-year overall survival
Presence or absence of progression
Pattern of progression (Presence or absence of progression of brain metastasis)
Post-treatment: 2nd treatment after the failure of alectinib treatment
Key secondary outcomes

Base
Study type Observational

Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria 1) 15 sites with participation to LOGIK1401 where patients were enrolled in LOGIK1401
2) Institutions approved by institutional ethics committee on this observational study.
Key exclusion criteria Nothing particular
Target sample size 18

Research contact person
Name of lead principal investigator Isamu Okamoto
Organization Kyushu University Hospital
Division name Research Institute for Disease of the Chest
Address 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan
TEL 092-642-5378
Email okamotoi@kokyu.med.kyushu-u.ac.jp

Public contact
Name of contact person Eiji Iwama
Organization Kyushu University Hospital
Division name Research Institute for Disease of the Chest
Address 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan
TEL 092-642-5378
Homepage URL
Email iwama@kokyu.med.kyushu-u.ac.jp

Sponsor
Institute Lung Oncology Group in Kyushu, Japan (LOGIK)
Institute
Department

Funding Source
Organization Clinical Research Support Center Kyushu
Organization
Division
Category of Funding Organization Non profit foundation
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions 九州大学病院(福岡県)、

Other administrative information
Date of disclosure of the study information
2019 Year 02 Month 12 Day

Progress
Recruitment status No longer recruiting
Date of protocol fixation
2018 Year 06 Month 28 Day
Anticipated trial start date
2018 Year 08 Month 15 Day
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Related information
URL releasing protocol
Publication of results Unpublished
URL releasing results
Results
Other related information Data collection
> Outcome (final survival date)
> Progression
Presence or absence of progression, pattern of progression (presence or absence of progression of brain metastasis): presence or absence of exacerbation or new emergence of brain metastases
> Post-treatment: next treatment after the failure of alectinib treatment, treatment period and detail.

Management information
Registered date
2019 Year 02 Month 12 Day
Last modified on
2019 Year 02 Month 12 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000040841

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.